An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

Conditions: Hepatitis C

Interventions: Drug: Telaprevir
1125 mg bid for 12 weeks
Drug: ribavirin
Initial dose of 600 mg total daily dose with goal of up to 1000mg-1200mg total daily dose based on body weight for 48 weeks
Drug: peginterferon alfa-2a
180 mcg/week for 48 weeks

Study Phase: Phase 2

Status: Recruiting

Study IDs: VX11-950-117 NCT01467505

To assess efficacy of telaprevir, peginterferon alfa-2a (Peg-IFN), and ribavirin (RBV) for HCV in a 48-week total treatment duration regimen following liver transplantation.

Study Description | Recruitment Information | Tracking Information | Administrative Information

ClinicalTrials.gov processed this record on 3/30/2012

Source: U.S. National Library of Medicine (NLM) and ClinicalTrials.gov.